We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ergon to Acquire Majority Stake in Elitech

By LabMedica International staff writers
Posted on 22 Nov 2010
Ergon Capital Partners (Brussels, Belgium), a mid-market private equity company, has signed an agreement to buy a majority stake in Elitech Group (Puteaux, France). More...


A leading independent manufacturer and distributor of in vitro diagnostic equipment, tests, and reagents, Elitech focuses on small to medium-sized, proximity, and emergency diagnostic laboratories. The Group is currently active in three segments of the diagnostics market: biochemistry, microbiology, and molecular diagnostics.

In the fiscal year ended March 31, 2010, Elitech Group reported proforma sales of US$125.7 million and Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) of $16.5 million.

Pierre Debiais, CEO of Elitech Group commented: "This is a strategically important step in the development of the Group. Ergon is a reputed investment institution, which will provide us with its expertise in the future transformation of the Group by bringing further professional qualities and capacity to the organization and by assisting us in making add-on acquisitions."

Ergon targets equity investment in companies located in France, Benelux, Italy, Spain, and Switzerland. Headquartered in Brussels, Ergon has offices in Paris, Milan, and Madrid. Ergon's investment philosophy is one of value creation in partnership with management, following an industrial strategy to generate long-term capital gains.

Related Links:

Elitech Group





New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.